although weak, correlation between the Heart Age and the stage of liver fi brosis rho (95% CI) of 0.3 (0.16, 0.45), P -value of <0.001 and the grade of hepatocyte ballooning [0.2 (0.05, 0.35), P =0.009]. Th ere was no correlation bet ween Heart Age and the grade of steatosis, lobular infl ammation or the overall NAFLD activity score ( Table 1 ) .
Our study, although limited by a small sample size, concludes that adults with biopsy-proven NAFLD have a signifi cant increase in Heart Age indicating an increase in overall cardiovascular risk. Liver fi brosis and ballooning should be investigated further as independent cardio vascular risk factors in this population. was to estimate the Heart Age in patients with biopsy-proven NAFLD and assess its correlation to the individual histologic features of NAFLD. Th e study included consecutive adult patients with biopsyproven NAFLD. Liver biopsies were evaluated by an experienced hepatopathologist and individual histologic features were evaluated using the Nonalcoholic Steatohepatitis Clinical Research Network criteria ( 3 ) . Th e stage of fi brosis was categorized from 0 to 4 ( 3 ) and Heart Age was calculated using the CDC online calculator. Overall, 170 patients were included, mean BMI of 32.8±4.9 kg m −2 , 51% male, 91% Caucasian, and 39% with type 2 diabetes. Th e mean actual age was 51.6±10.2 years compared with a calculated Heart Age of 67.6±17.1 years, indicating a signifi cant increase in Heart Age in this population with a mean diff erence (95% CI) of 16.0 (14.4, 17.9) years, P -value <0.001 ( Figure 1 ). Furthermore, there was a signifi cant, Heart Age -Actual Age Reactivation of HBV in patients with chronic HCV treated with DAAs has only recently been described. Historically, it has been hypothesized that in patients coinfected with HCV and HBV, one virus usually asserts dominance and commonly these patients have active HCV viremia with low or undetectable HBV DNA levels. Th e mechanism by which chronic HCV may suppress HBV replication has a few possible explanations including (1): HBV antigen levels are reduced in the hepatocytes and in the periphery of chronically co-infected patients ( 3 ) (2) patients with chronic HBV have higher rates of surface antigen clearance following HCV superinfection ( 4 ), and (3) viral replication in acute HBV infection may be attenuated in patients with preexisting HCV.( 5 ) Studies have also shown that both HCV and HBV can replicate in the same cell( 6 ) without direct interference, suggesting that viral dominance may be an indirect, rather than direct mechanism, mediated by the host immune system.
CONFLICT OF INTEREST
In review of the current literature, aside from our recently published series,( 7 ) three additional case reports of hepatitis B reactivation with DAAs have been described( 8-10 ) (see Table 1 ). While previous IFN-based therapy had treatment eff ect on both HBV and HCV, DAAs do not off er any antiviral activity against HBV. In our series, both patients had a rapid decline in HCV VL with DAA therapy, and attained a SVR-12. Both patients also responded to HBV antiviral therapy and none of our patients developed irreversible hepatic decompensation.
Our experience emphasizes the importance of not only identifying patients with Letters to the Editor active hepatitis B viremia but also closely
